Fonseca TL, Teixeira MB, Rodrigues-Miranda M, Silva MV, Martins GM, Costa CC, Arita DY, Perez JD, Casarini DE, Brum PC, Gouveia CH. Thyroid hormone interacts with the sympathetic nervous system to modulate bone mass and structure in young adult mice. Am J Physiol Endocrinol Metab 307: E408 -E418, 2014. First published July 8, 2014; doi:10.1152/ajpendo.00643.2013.-To investigate whether thyroid hormone (TH) interacts with the sympathetic nervous system (SNS) to modulate bone mass and structure, we studied the effects of daily T3 treatment in a supraphysiological dose for 12 wk on the bone of young adult mice with chronic sympathetic hyperactivity owing to double-gene disruption of adrenoceptors that negatively regulate norepinephrine release, ␣2A-AR, and ␣2C-AR (␣2A/2C-AR Ϫ/Ϫ mice). As expected, T3 treatment caused a generalized decrease in the areal bone mineral density (aBMD) of WT mice (determined by DEXA), followed by deleterious effects on the trabecular and cortical bone microstructural parameters (determined by CT) of the femur and vertebra and on the biomechanical properties (maximum load, ultimate load, and stiffness) of the femur. Surprisingly, ␣2A/2C-AR Ϫ/Ϫ mice were resistant to most of these T3-induced negative effects. Interestingly, the mRNA expression of osteoprotegerin, a protein that limits osteoclast activity, was upregulated and downregulated by T3 in the bone of ␣2A/2C-AR Ϫ/Ϫ and WT mice, respectively. ␤1-AR mRNA expression and IGF-I serum levels, which exert bone anabolic effects, were increased by T3 treatment only in ␣2A/2C-AR Ϫ/Ϫ mice. As expected, T3 inhibited the cell growth of calvaria-derived osteoblasts isolated from WT mice, but this effect was abolished or reverted in cells isolated from KO mice. Collectively, these findings support the hypothesis of a TH-SNS interaction to control bone mass and structure of young adult mice and suggests that this interaction may involve ␣2-AR signaling. Finally, the present findings offer new insights into the mechanisms through which TH regulates bone mass, structure, and physiology. thyroid hormone; sympathetic nervous system; bone; ␣-adrenoceptors; ␤-adrenoceptors THYROID HORMONE (TH) is essential for normal bone development, maturation, and metabolism. Hypothyroidism retards bone growth and slows bone turnover (3), whereas thyrotoxicosis is frequently associated with accelerated bone development and metabolism and decreased bone mass (43). Histomorphometric studies indicate that thyrotoxicosis increases both osteoblastic and osteoclastic activities, but the latter predominates. As a result, bone turnover is accelerated, favoring bone resorption, a negative balance of calcium, and bone loss (26, 41). Although the negative effects of overt thyrotoxicosis to bone mass and turnover are well known, the mechanisms by which TH promotes its effects are less clear. TH can affect the skeleton indirectly through changes in other hormones, e.g., growth hormone and IGF-I (31, 33), but in vitro studies show that 3,3=,5-triiodo-L-thyronine (T 3 ) also acts directly in bone cells, modifying their proliferation, differentiation and/or expression of several bone-related genes (27, 39, 69, 70) . It is generally accepted that most T 3 actions are mediated by its nuclear receptors, which were shown to be expressed in osteoblasts (70), osteoclasts (1), and chondroblasts (4).
loss (26, 41) . Although the negative effects of overt thyrotoxicosis to bone mass and turnover are well known, the mechanisms by which TH promotes its effects are less clear. TH can affect the skeleton indirectly through changes in other hormones, e.g., growth hormone and IGF-I (31, 33) , but in vitro studies show that 3,3=,5-triiodo-L-thyronine (T 3 ) also acts directly in bone cells, modifying their proliferation, differentiation and/or expression of several bone-related genes (27, 39, 69, 70) . It is generally accepted that most T 3 actions are mediated by its nuclear receptors, which were shown to be expressed in osteoblasts (70) , osteoclasts (1) , and chondroblasts (4) .
Recently, the sympathetic nervous system (SNS) was identified as an important and potent regulator of bone metabolism (17, 61) . A series of studies suggest that the SNS negatively regulates bone formation and positively regulates bone resorption via ␤ 2 -adrenoceptor (␤ 2 -AR) signaling, which is expressed in osteoblasts. Administration of propranolol, a ␤-blocker, and isoproterenol, a ␤-agonist, was demonstrated to increase and decrease bone mass, respectively, in adult animals (8, 10, 60) . The role of the SNS in controlling bone mass was supported by a high-bone mass (HBM) phenotype in an animal model of low SNS activity, a mouse deficient for dopamine ␤-hydroxylase (DbH Ϫ/Ϫ ), the step-limiting enzyme responsible for catecholamine synthesis (10, 46) . A more precise role of ␤-adrenergic signaling on bone mass was supported by the analysis of mice with global gene deletion of ␤ 2 -AR (␤ 2 -AR Ϫ/Ϫ ). These animals do not exhibit endocrine and metabolic abnormalities, have a normal body weight, and exhibit a HBM phenotype beginning at 6 mo of age due to an increase in bone formation and a decrease in bone resorption (18) .
However, a recent study by our group demonstrated that young adult mice with global double-gene inactivation of ␣ 2A and ␣ 2C adrenoceptors (␣ 2A/2C -AR Ϫ/Ϫ ) also exhibit a phenotype of HBM that becomes more evident as the animals age (from 40 to 120 days of age) despite exhibiting chronic sympathetic hyperactivity and intact ␤ 2 -AR (19) . The ␣ 2 -adrenergic receptors (␣ 2 -ARs) were characterized initially as presynaptic autoreceptors that negatively regulate catecholamine release (13, 29) . Later, it was shown that ␣ 2 -ARs are not restricted to presynaptic sites but can also have postsynaptic locations and functions, which include the regulation of body temperature, intraocular pressure, lipolysis, and pain perception (12, 28, 47) . Three subtypes of ␣ 2 -ARs have been identified: ␣ 2A -AR, ␣ 2B -AR, and ␣ 2C -AR (15, 32, 47) . Hein et al. (29) reported that the double blockage of ␣ 2A -AR and ␣ 2C -AR in mice results in increased serum levels of norepinephrine (NE) . In addition to the HBM phenotype, we found that ␣ 2A/2C -AR Ϫ/Ϫ mice exhibit increased bone formation and decreased bone resorption (19) . Consistent with a previous study that identified the presence of ␣ 2 -AR isoforms in humanderived bone cells (61) , we demonstrated the mRNA expression of ␣ 2A -, ␣ 2B -, and ␣ 2C -AR in the bone of mice and in osteoblast-like cells derived from the mouse calvarium (MC3T3-E1 cells). By immunohistochemistry, we found that ␣ 2A -, ␣ 2B -, ␣ 2C -, and ␤ 2 -AR are expressed in osteoblasts, osteocytes, osteoclasts, and chondrocytes from fetal and adult mice (19) . Collectively, these findings raise the hypothesis that ␣ 2 -AR may also mediate SNS signaling in the skeleton.
There is evidence that TH interacts with the SNS to control several physiological processes. It is known that this interaction is required for maximal thermogenesis, lipolysis, and glycogenolysis (45) . In addition, many of the clinical features of hyperthyroidism, such as palpitations, tremor, sweating, nervousness, weight loss, heat intolerance, stare, tachycardia, and increased pulse pressure, mimic the manifestations of excess ␤-adrenergic activity and indicate that thyrotoxicosis results in a state of hyperadrenergic stimulation (22, 49) . ␤-Adrenergic blockage profoundly modifies the severity of these symptoms, and their use in the management of hyperthyroidism is well established (34, 35, 50, 63, 64) .
Considering the negative effects of thyrotoxicosis and SNS activation on bone mass, we raised the hypothesis that TH may also interact with the SNS to regulate bone metabolism. A piece of evidence supporting this possible interaction is the fact that the treatment of hyperthyroid patients with propranolol corrects their hypercalcemia (53) and decreases their urinary excretion of hydroxyproline, a biochemical marker of bone resorption (6) .
The aim of the present study was to investigate whether TH interacts with the SNS to regulate bone mass and structure during young adulthood in mice, a phase of important bone mass accrual and growth. We observed that young adult ␣ 2A/2C -AR Ϫ/Ϫ mice are resistant to the deleterious effects of thyrotoxicosis on bone. These findings strongly suggest that adrenergic signaling modulates TH actions in the bone.
MATERIALS AND METHODS
Animal maintenance and manipulation. A cohort of female congenic ␣ 2A/2C-AR-knockout (KO) mice in a C57BL/6J (B6) background and their wild-type (WT) controls were studied from 40 to 123 days of age, a phase of important bone mass accrual and growth (25) . The animals were considered young adults, since the pubertal maturation in B6 female mice begins when serum estradiol increases by day 26 after birth and is complete when vaginal opening occurs by day 31 (2) . Animals received intraperitoneal injections of T 3 (SigmaAldrich, Munich, Germany) in a daily dose that corresponds to ϳ10 times its physiological dose (10 ϫ T3 ϭ 3.5 g·100 g body wt Ϫ1 ·day Ϫ1 ) and is known to induce bone loss (21) . T3 injections were administered every day, at the same time each day. Animals (n ϭ 7 animals/group) were treated for 12 wk. Body weight was measured every week, and the amount of hormone administered was adjusted according to the changes in body weight to maintain the proper dosage. All experimental procedures were performed in accordance with the guidelines of the Standing Committee on Animal Research of the University of Sao Paulo (protocol no. 065-17/02), which approved the study.
Serum levels of T 3, thyroxine, and IGF-I. At the end of the experimental period the animals were euthanized, and the blood was collected. Serum levels of total thyroxine (T 4) and T3 were measured using radioimmunoassay commercial kits (RIA-gnost T 4 and RIAgnost T 3; CIS Bio International, Schering, Paris, France). Serum IGF-I levels were measured by RIA (Diagnostic System Laboratories, Webster, TX).
Femur and plasma levels of cathecholamines. For cathecolamine extraction, the two whole femurs of each animal were crushed in a steel mortar and pestle set (Fisher Scientific International, Hampton, NH) precooled in dry ice. The crushed bones were weighed and homogenized in 1.5 ml of cold 0.1 M perchloric acid containing 0.02% sodium pyrosulfite (Na 2S2O5) and 0.7 nM 3,4-dihydroxybenzylamine hydromide as an internal standard. The homogenates were kept at 4°C overnight and centrifuged at 10,000 rpm for 50 min at 4°C. The supernatants were stored at Ϫ80°C until they were assayed for NE and epinephrine (EP). Femur and plasma levels of cathecholamines were measured by HPLC using ion-pair reverse-phase chromatography coupled with electrochemical detection (0.5 V), as described previously (40, 42) .
Determination of areal bone mineral density by dual-energy X-ray absorptiomettry. Areal bone mineral density (aBMD) was measured using the pDXA Sabre Bone Densitometer and the pDXA Sabre Software version 3.9.4 (Norland Medical Systems, Fort Atkinson, WI), both of which were especially designed for small animals. The research mode scan option was used for the measurements. Pixel spacing for the scan was set to 0.5 ϫ 0.5 mm and the scan speed to 4 mm/s. To limit the scan area, which allows the scans to be performed in a higher-resolution mode, the scans were performed from the first lumbar vertebra to the hindlimbs. The regions of interest for analysis were 1) the hind body, which includes the lumbar spine, pelvic bones, and hindlimbs; 2) lumbar vertebrae (L1-L6); 3) both femurs; and 4) both tibias. Taking into account the possibility of bone mass differences between the left and right limbs as a result of functional bilateral asymmetry (20) , the aBMD of femur and tibia was expressed as the mean of the left and right limbs for each animal. For the scans, the animals were anesthetized with a ketamine and xylazine cocktail (10 and 30 mg/kg body wt) and scanned in the prone position. The animals were subjected to a basal scan and to scans after 4 and 12 wk of treatment.
Microcomputed tomography analysis. The microarchitecture of the femur and lumbar vertebra (L6) was investigated using a microcomputed tomography (CT) unit (SkyScan 1172; SkyScan, Aartselaar, Belgium) in which the samples were rotated through 360°at a rotation step of 0.5°. The X-ray settings were standardized to 100 kV for the baseline bone specimens, with an exposure time of 590 (ms). A 0.5-mm-thick aluminum filter and a beam-hardening algorithm were used to minimize beam-hardening artifacts. The registered data sets were segmented into binary images. The two-(2D) and three-dimensional (3D) measurements were obtained with the CTAn version 1.5 (SkyScan). The distal metaphysis of the femur and the vertebral body of L6 were selected as the regions of interest for the trabecular bone analysis. The following 3D structural parameters were determined from ϳ180 and 210 transverse femoral and vertebral CT slices, respectively: trabecular bone volume (BV/TV), trabecular thickness (Tb.Th), trabecular number (Tb.N), trabecular separation (Tb.Sp), trabecular porosity (Tb.Po), structure model index (SMI), trabecular pattern factor (Tb.PF) and volumetric bone mineral density (vBMD). Morphometric variables of cortical bone were measured in the femoral diaphysis and in the vertebral body (ϳ170 and 70 transverse CT slices) from the distal limit of the pedicles until the distal growth plate. The cortical thickness (Ct.Th), tissue area (T.Ar), cortical area (Ct.Ar), medullary area (Ma.Ar), cortical bone volume (Ct.BV), and the polar moment of inertia (MMI) were measured in 2D crosssectional images. The cortical porosity (Ct.Po) and vBMD were measured in 3D. To guarantee that the same bone regions were measured in every sample, the number of transverse CT slices per sample was calculated accordingly to the respective bone length (femur or vertebra).
Three-point bending test. The right femurs were tested in an Instron testing machine (Model 3344; Instron, Norwood, MA). Fresh-frozen bones were thawed to room temperature (22°C). The anterior cortex at the middiaphysis of the femur was placed in compression and the posterior cortex in tension during the test. The lower support points were separated by an span of 50% of the femoral length (femur length/2). A constant displacement rate of 0.03 mm/s was applied until the bone fractured. Fracture was taken as the complete loss of load-carrying ability. To stabilize the specimen, a small preload (5% of the average maximal load) was applied before actual testing. During the bending test, load displacement data were collected by a computerized data acquisition system at a sampling rate of 80 Hz. The biomechanical properties evaluated were the maximum load [a measurement of the maximum force that the bone withstood before fracture (N)], ultimate load [the load at the fracture point (N)], resilience [a measurement of the ability of a bone to suffer elastic deformity (J)], Young's modulus (mPa), and stiffness (N/mm) (the last two of which are measurements of the extrinsic rigidity of the bone tissue).
Real-time PCR. Expression of ␣ 2A-AR, ␣2C-AR, ␤2-AR, ␤1-AR, receptor activator of nuclear factor-B (RANK), RANK ligand (RANK‫گ‬L), and osteoprotegerin (OPG) were determined by real-time PCR, as described previously (14) in the whole tibia. Briefly, the total RNA was extracted using Trizol (Invitrogen, Carlsbad, CA), following the manufacturer's instructions. Total RNA was reverse transcribed using RevertAid-H-Minus M-MuLV Reverse Transcriptase (Fermentas, Hanover, MD) to synthesize the first-strand cDNA, which was used as a template. SYBR Green Super Mix (Applied Biosystems, Warrington, UK) was used for the real-time PCR using the ABI Prism 7500 sequence detector (Applied Biosystems, Foster City, CA). All CT values were normalized using an internal control: 18S or ␤-actin mRNA. Both internal controls were validated for this study, showing to be stable (their expression did not vary due to mice lineage or T3 treatment). Relative gene expression quantification was assessed by the ⌬⌬CT method, as described previously by Livak (36) . The final values for samples are reported as fold induction relative to the expression of the control, with the mean control value being arbitrarily set to 1.
Calvaria-derived osteoblastic cell growth. Primary mouse osteoblastic cells were obtained by sequential enzyme digestion of excised calvarial bones from neonatal WT and ␣2A/2C-AR Ϫ/Ϫ mice, using 1% trypsin and 1% collagenase in ␣-MEM (Gibco BRL, Paisley, UK). Osteoblasts were initially seeded at a density of 10 4 cells/well in 24-well plates and cultured in growth media containing ␣-MEM (Invitrogen) supplemented with 10% FBS (Gibco) and 1% penicillinstreptomycin (Gibco). After 72 h (day 0), the culture medium was changed to the differentiation medium, growth media were supplemented with 50 g/ml ascorbic acid (Sigma, St. Louis, MO) and 10 mM ␤-glycerophosphate (Sigma), and the treatment with T3 (10 Ϫ8 M) and/or clonidine (CLO; 10 Ϫ6 M) was initiated. Medium was changed every 3 days. The cells were collected on day 0 and after 3, 6, and 9 days of treatment to determine the cell number and viability by direct counting with a Neubauer Chamber (Improve Neubaur). Cell viability was determined by the Trypan blue exclusion method, with cells suspended in 0.4% Trypan blue dye (1:2 dilution; Gibco-BRL, Grand Island, NY). Cells were assayed in quadruplicates.
Statistical analysis. Results are presented as means Ϯ SE. Twoway analysis of variance was used to compare TH effects in WT and KO mice and cells and was always followed by Tukey's test to detect differences between groups. The unpaired Student t-test was used for pairwise comparisons of the groups. For all tests, significance was defined as P Ͻ 0.05. For statistical analyses, we used the GraphPad Instat software package (GraphPad Software, San Diego, CA).
RESULTS

Sympathetic hyperactivity and induction of a thyrotoxic state in ␣ 2A/2C -AR
Ϫ/Ϫ mice. We evaluated the effect of daily administration of 10 times the physiological dose of T 3 for 12 wk on bone of WT and ␣ 2A/2C -AR Ϫ/Ϫ mice, which is an animal model of chronic elevated sympathetic tone. T 3 treatment increased the serum concentration of T 3 19-fold and consequently decreased T 4 serum levels 10-and 11-fold in WT and KO mice, respectively (Table 1) , which reflects TSH inhibition by negative feedback (68) . Serum T 3 levels were not different between T 3 -treated and untreated WT and KO mice; however, untreated KO mice presented 31% higher serum T 4 levels than untreated WT mice. As expected, we observed that plasma levels of NE and EP were higher in ␣ 2A/2C -AR Ϫ/Ϫ mice compared with WT mice (Fig. 1, A and B) . Accordingly, the femur concentration of NE was 96% higher in the bones of KO mice compared with WT mice (Fig. 1C) , whereas EP bone concentration was not different between WT and KO mice. Interestingly, T 3 treatment decreased NE and EP plasma levels (by 37 and 62%, respectively) only in WT mice (Fig. 1, A and B), whereas T 3 decreased NE concentration (by 53%) only in the bones of ␣ 2A/2C -AR Ϫ/Ϫ mice (Fig. 1C) , bringing the bone NE concentration of KO mice to the level of WT mice (KO ϩ T 3 ϭ WT). Corroborating previous studies that reported cardiac hypertrophy in conditions of thyrotoxicosis, T 3 treatment significantly and equally increased heart mass in WT (WT ϭ 1.07 Ϯ 0.02 vs. WT ϩ T 3 ϭ 1.35 Ϯ 0.11, P Ͻ 0.05) and KO Data are presented as means Ϯ SE and in ng/ml (n ϭ 7/group). T3, 3,3=,5-triiodo-L-thyroxine; T4, thyroxine; ␣2A/2C-AR, ␣2A/2C-adrenoceptor; WT, wild type; KO, knockout; NS, nonsignificant. Significance between the groups was determined by 2-way ANOVA followed by Tukey's test. animals (KO ϭ 1.16 Ϯ 0.02 vs. KO ϩ T 3 ϭ 1.46 Ϯ 0.01, P Ͻ 0.05), which confirms the toxicity of the regimen of T 3 treatment used in this study. According to previous studies that applied the same dose (66) or fourfold (57) the dose of T 3 used in the present study, body weight and body length were not affected by TH administration in WT and KO animals. However, BW was significantly higher (ϳ13%) in KO mice during the whole experimental period (P Ͻ 0.01).
TH effects on serum levels of IGF-I. Since there is evidence that the growth hormone-IGF-I axis may mediate the adrenergic signaling (9, 48) and TH actions in bone (31, 33), we measured serum levels of IGF-I, which were significantly increased (24%) by T 3 treatment only in ␣ 2A/2C -AR Ϫ/Ϫ mice and not in WT mice (Table 1) .
TH effects on the aBMD of ␣ 2A/2C -AR Ϫ/Ϫ mice. As predicted, thyrotoxicosis was detrimental to the aBMD of WT mice, significantly impairing bone mass acquisition in all skeletal sites evaluated (Fig. 2) . The aBMD of the hind body (lumbar spine, pelvis, and hindlimbs), lumbar vertebrae (L1-L6), femur, and tibia of WT mice treated with T 3 for 12 wk was 11, 14, 13, and 9% lower, respectively, compared with euthyroid WT mice. Surprisingly, the bones of ␣ 2A/2C -AR Ϫ/Ϫ mice were found to be resistant to the osteopenic effects of TH excess, as the supraphysiological dose of T 3 had no effect on the aBMD of KO mice. This critical finding strongly suggests that TH interacts with the SNS to regulate bone mass.
TH effects on the bone microarchitecture of
mice. The CT data of the trabecular bone structure of the distal methaphysis of the femur (Fig. 3, A-H (Fig. 3B) , which was also decreased by T 3 in KO mice (30%). The comparison of WT vs. KO mice shows higher femoral Tb.N in ␣ 2A/2C -AR Ϫ/Ϫ animals (Fig. 3B) . Considering the T 3 -treated animals, we found higher BV/TV, Tb.N, Tb.Th, and vBMD and lower Tb.Sp, Tb.Po, and Tb.Pf in KO vs. WT mice, which strengthens the resistance of the femoral trabecular bone of KO mice to the deleterious effects of thyrotoxicosis. The trabecular bone of the vertebra was less sensitive to the TH effects (Fig. 3, I-P) . T 3 treatment significantly decreased trabecular vBMD (14%) only in WT (Fig. 3P) and decreased BV/TV (29%) only in KO mice (Fig.  3I ). According to previous findings (19) , vertebral BV/TV (Fig. 3I ) was higher and vertebral Tb.Po (Fig. 3M) and SMI (Fig. 3O) were lower in untreated WT vs. untreated KO mice. The CT analysis of the cortical bone of the femoral diaphysis demonstrated that T 3 treatment decreased Ct.Th (22%), T.Ar (25%), Ct.Ar (25%), Ma.Ar (49%), and Ct.BV (25%) and increased Ct.Po (9%) only in WT mice (Fig. 4, A-F) . The comparison of WT vs. KO mice shows higher cortical vBMD (Fig. 4H ) in ␣ 2A/2C -AR Ϫ/Ϫ animals, which corroborates the DEXA findings. Taking into account the T 3 -treated animals, we found higher femoral Ct.Th, T.Ar, Ct.Ar, Ma.Ar, and Ct.BV and lower Ct.Po in KO vs. WT mice, which supports the resistance of the femoral cortical bone of KO mice to the deleterious effects of thyrotoxicosis. The cortical bone of vertebra (L6) was negatively affected by thyrotoxicosis in both WT and KO mice. T 3 treatment reduced Ct.Th (22% in WT and 32% in KO), Ct.Ar (46% in WT and 35% in KO), Ct.BV (46% in WT and 38% in KO), and MMI (45% in WT and 38% in KO) in WT and ␣ 2A/2C -AR Ϫ/Ϫ animals (Fig. 4, I -K, M, and O). However, T 3 treatment reduced T.Ar (45%) and increased Ct.Po (14%) only in the vertebra of WT animals. Corroborating the DEXA findings, Ct.BV and cortical vBMD of L6 were higher in the KO mice (Fig. 4, M and P, respectively) .
TH effects on the bone biomechanical parameters of ␣ 2A/2C -AR Ϫ/Ϫ mice. In accord with DEXA and CT findings, the three-point bending test showed that the femoral maximum load, ultimate load, and stiffness were decreased significantly by T 3 treatment only in WT mice and not in ␣ 2A/2C -AR Ϫ/Ϫ animals ( Fig. 5, A-C) . In addition, we found lower femoral maximum load, ultimate load, stiffness, young's modulus, and resilience in WT ϩ T 3 than in KO ϩ T 3 mice (Fig. 5) . No significant differences were found in any of the biomechanical parameters tested between untreated WT and KO mice. Altogether, these data indicate a resistance of the KO mice to the deleterious effects of thyrotoxicosis also on the biomechanical features of the femur.
Effect of T 3 treatment on the gene expression of the RANKL/ RANK/OPG system. To further investigate a possible interaction between TH and the SNS in the bone, we evaluated the effect of T 3 on the gene expression of the RANKL/RANK/ OPG system, which plays a pivotal role in bone remodeling by regulating osteoclast formation and activity (67) . T 3 treatment had no effect on the expression of RANK or RANKL (Fig. 6,  A and B) in either WT or KO animals. On the other hand, OPG mRNA expression was decreased (66%) by T 3 treatment in WT mice and increased (2-fold) by T 3 treatment in KO animals (Fig. 6C) , which may partially explain the osteopenic effect of T 3 in WT mice but not in KO mice. Surprisingly, OPG mRNA expression was shown to be lower in KO mice vs. WT mice.
Effect of T 3 treatment on the expression of adrenoceptors in bone. T 3 treatment increased the mRNA expression of ␤ 1 -AR in the bone of ␣ 2A/2C -AR Ϫ/Ϫ mice by 40% (P Ͻ 0.05) but did not increase expression in the bone of WT animals (Fig. 7A) . On the other hand, T 3 treatment decreased ␤ 2 -AR mRNA expression by 33% in WT but not in KO mice (Fig. 7B) . In WT animals, T 3 treatment had no effect on the bone expression of ␣ 2A -AR mRNA (Fig. 7C ) but decreased ␣ 2C -AR mRNA expression significantly by 30% (Fig. 7D ). There were no significant differences between WT and KO animals regarding the mRNA expression of adrenoceptors in the bone.
Calvaria-derived osteoblastic cells from WT and ␣ 2A/2C -AR
Ϫ/Ϫ respond differently to T 3 and CLO. We tested the effect of T 3 treatment on cell growth of osteoblasts derived from WT and ␣ 2A/2C -AR Ϫ/Ϫ mice (Fig. 8A) . T 3 (10 Ϫ8 M) decreased the growth of WT cells significantly after 3, 6, and 9 days of treatment, which corroborates previous studies (5, 65, 70) . On the other hand, in KO cells, T 3 treatment for 3 days had no effect on cell growth, whereas 6 and 9 days of treatment increased this parameter. Compared with WT cells, untreated KO cells grew significantly less during the whole experimental period (Fig. 8A) , suggesting that ␣ 2A -AR and/or ␣ 2C -AR have ) or saline for 12 wk. Values are expressed as means Ϯ SE (n ϭ 6/group). *P Ͻ 0.05, **P Ͻ 0.01, and ***P Ͻ 0.001 vs. the respective saline-treated animals (WT vs. WT ϩ T3 or KO vs. KO ϩ T3). Nos. above the bars indicate the P values for differences between WT and KO mice, as indicated. BV/TV, trabecular bone volume; Tb.N, trabecular number; Tb.Th, trabecular thickness; Tb.Sp, trabecular speculation; Tb.Po, trabecular porosity; Tb.PF, trabecular pattern function; SMI, structure model index; vBMD, volumetric bone mineral density. a function on the regulation of this process. Next, WT and KO cells were treated with CLO, an unspecific ␣ 2 -AR agonist, alone or combined with T 3 to test whether ␣ 2 -adrenoceptors are functional in osteoblastic cells and whether their activation modifies the responsiveness of these cells to T 3 . In WT cells (Fig. 8B) , CLO or T 3 treatment for 3, 6, and 9 days decreased cell growth significantly, whereas the combination of both agents promoted a higher decrease than T 3 alone, in an additive manner. In contrast, in KO cells (Fig. 8C) , CLO increased cell growth after 3, 6, and 9 days of treatment. T 3 also increased KO cell growth, but not as much as CLO and only after 6 and 9 days of treatment. The combination of both agents showed ·day Ϫ1 ) or saline for 12 wk. Values are expressed as means Ϯ SE (n ϭ 6/group). *P Ͻ 0.05 and **P Ͻ 0.01 vs. the respective saline-treated animals (WT vs. WT ϩ T3). Nos. above the bars indicate the P values for differences between WT ϩ T3 and KO ϩ T3 mice.
that the effect of T 3 was not modified by CLO in KO cells; however, T 3 significantly attenuated the effect of CLO on cell growth after 3 and 6 days of treatment. Cell viability, assessed by Trypan blue exclusion, was always Ն90% and was not affected by T 3 or CLO treatment at any time point tested in either cell lineage. Since cell viability was not affected by both agents, it is likely that their effects in cell growth were mainly the result of an effect in cell proliferation rather than in cell death.
DISCUSSION
To investigate whether the osteopenic effects of TH excess could depend on SNS activation, we evaluated whether the thyrotoxicosis-induced osteopenia is intensified in ␣ 2A/2C -AR Ϫ/Ϫ mice, which exhibit elevated plasma NE and intact ␤ 2 -AR (29) . Interestingly, these mice exhibit a phenotype of HBM despite their elevated sympathetic tone, which is strong evidence that ␤ 2 -AR is not the unique adrenoceptor involved in the control of bone turnover and raises the hypothesis that ␣ 2 -ARs may also mediate SNS signaling in the skeleton (19) . Treatment with the supraphysiological dose of T 3 for 12 wk promoted the characteristic effects of thyrotoxicosis (30, 54, 55) , including cardiac hypertrophy both in WT and KO mice, and a generalized decrease in aBMD in WT mice determined by DEXA. In contrast, a surprising and very interesting finding was that ␣ 2A/2C -AR Ϫ/Ϫ mice were resistant to the thyrotoxicosis-induced osteopenia, as the supraphysiological dose of T 3 had no effect on their bone mass. The CT analysis substantiates the resistance of ␣ 2A/2C -AR Ϫ/Ϫ mice to the osteopenic effects of TH excess. As expected, thyrotoxicosis negatively affected most of the microarchitectural features of the distal metaphysis trabecular bone and midshaft cortical bone of the femur in WT but not in ␣ 2A/2C -AR Ϫ/Ϫ mice. These findings were accompanied by T 3 -induced declines in the biomechanical properties (maximum load, ultimate load, and stiffness) of the femur only in WT and not in KO mice. Corroborating previous studies that show that TH preferentially affects femoral but not vertebral bone (26, 44, 51, 59) , the microstructural parameters of the trabecular bone of L6 were barely affected by T 3 treatment. However, the trabecular vBMD of L6, determined by CT, was decreased significantly by TH treatment only in WT mice and not in KO mice, which is in agreement with the aBMD findings determined by DEXA. On the other hand, the cortical bone of L6 was negatively affected by thyrotoxicosis both in WT and KO mice. Nevertheless, it was slightly more affected by TH in WT than in KO mice, since T 3 treatment decreased T.Ar and increased Ct.Po of L6 in WT but not in KO mice. Altogether, these results strongly suggest that TH excess depends on intact ␣ 2 -AR signaling to negatively regulate bone mass, structure, and biomechanical resistance, especially in the femur. The fact that the double-gene deletion of ␣ 2A -and ␣ 2C -AR prevented the negative effects of TH in the femoral cortical bone but not in the vertebral cortical bone suggests that the TH-SNS interaction may vary depending on the skeletal site. In fact, several studies show that the THadrenergic interrelationships are by no means uniform from tissue to tissue, from organ to organ, or in different regions of the same organ (56). Fig. 6 . Effect of thyroid hormone excess on the relative mRNA expression of the receptor activator of nuclear factor-B (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) system (A-C) in WT and ␣2A/2C-AR Ϫ/Ϫ mice, as determined by real-time PCR analysis. Animals were treated with a supraphysiological dose of T3 (3.5 g·100 g body wt Ϫ1 ·day Ϫ1 ) or saline (-) for 12 wk. mRNA expression was determined by real-time PCR analysis. Values are expressed as means Ϯ SE (n ϭ 6/group). *P Ͻ 0.05 and **P Ͻ 0.01 vs. the respective saline-treated animals (WT vs. WT ϩ T3 or KO vs. KO ϩ T3). Nos. above the bars indicate the P values for differences between WT and KO, as indicated. ) or saline (-) for 12 wk. mRNA expression was determined by real-time PCR analysis. Values are expressed as means Ϯ SE (n ϭ 6/group). *P Ͻ 0.05 and **P Ͻ 0.001 vs. the respective saline-treated animals (WT vs. WT ϩ T3 or KO vs. KO ϩ T3). Nos. above the bars indicate the P values for differences between WT and KO, as indicated.
We also evaluated the effect of TH on the RANK/RANKL/ OPG system. RANKL, expressed by the osteoblasts, is the ligand of RANK (an osteoclast plasma membrane receptor) and the main inducer of osteoclast formation, function, and survival (67) . OPG, also expressed by the osteoblasts, is the natural inhibitor of osteoclastic activity, since it binds RANKL and thereby impairs RANKL/RANK association. T 3 significantly increased OPG mRNA expression in ␣ 2A/2C -AR Ϫ/Ϫ mice and decreased OPG mRNA expression in WT mice. This finding is consistent with the osteopenic effect of T 3 in WT but not in ␣ 2A/2C -AR Ϫ/Ϫ mice and suggests that the RANK/ RANKL/OPG system may partially mediate TH actions in the bone. Additionally, it suggests that this mediation is affected by modifications in SNS signaling, which in turn reinforces a TH-SNS interaction to regulate bone physiology.
The interaction of TH with the SNS is normally complex and may occur at multiple levels (56) . TH generally potentiates ␤-AR signals, and it occurs in different ways, depending on the tissue or organ (56) . Certainly, one mechanism whereby TH can alter these signals is by modifying the expression of adrenoceptors (7) . Considering this mechanism, we first evaluated whether TH could modify the mRNA expression of ␤ 1 -and ␤ 2 -AR in the bone. We found that TH decreased ␤ 2 -AR mRNA expression only in the bone of WT mice. In contrast, T 3 treatment increased ␤ 1 -AR mRNA expression only in the bone of ␣ 2A/2C -AR Ϫ/Ϫ mice. These findings once more show that the absence of ␣ 2A -AR and/or ␣ 2C -AR alters the way that bone responds to thyrotoxicosis, supporting the hypothesis of a TH-SNS interaction to regulate bone physiology. It is well known that TH can modify the number of ␤-ARs, but again, this effect is not the same in all tissues, nor does it include all isoforms (7, 52) . As a consequence of thytoxicosis, for example, the number of ␤-ARs has been shown to be increased in rat heart muscle and brown adipose tissue, decreased in rat liver, and increased or not changed in rat white adipose tissue and human leukocytes (7) . It is noteworthy that ␤ 1 -AR KO mice exhibit low bone mass, which suggests that this receptor mediates the anabolic actions of the SNS in the bone (11) . In fact, a recent study indicates that ␤ 1 -AR exerts predominant and opposite effects of ␤ 2 -AR on bone remodeling through both systemic and local factors (48) . Moreover, evidence indicates that the anabolic effects of ␤ 1 -AR signaling are partially mediated by systemic IGF-I, which should be upregulated by ␤ 1 -AR activation (48) . Interestingly, in the present study, we found that TH treatment increased IGF-I serum levels only in ␣ 2A/2C -AR Ϫ/Ϫ mice, which exhibited elevated ␤ 1 -AR mRNA expression. Thus, the positive effect of T 3 treatment on ␤ 1 -AR mRNA expression and on IGF-I serum levels in ␣ 2A/2C -AR Ϫ/Ϫ mice, but not in WT mice, may partially explain the resistance of KO mice to the TH-induced osteopenia.
We also found that T 3 treatment reduced ␣ 2C -AR mRNA expression but not ␣ 2A -AR mRNA expression in the bone of WT mice. The effect of TH on ␣-ARs has been much less investigated than on ␤-ARs. In general, it seems that TH decreases the expression of ␣-ARs (7), which corroborates our findings. Besides bone, it was observed in the heart, liver, and white adipose tissue (7) . The physiological implication of the T 3 -induced reduction in ␣ 2C -AR mRNA expression observed in the present study cannot be inferred at this point. However, the thyrotoxicosis-induced modulation of ␤ 1 -AR, ␤ 2 -AR, and ␣ 2C -AR mRNA expression observed in the bone suggests that these adrenoceptors may be sites of interaction between TH and the SNS to regulate bone structure and physiology. Nevertheless, it is important to consider that the adrenoceptors themselves are only two of many sites of TH-SNS interaction. Furthermore, T 3 -induced modifications in adrenoceptors are usually modest or nonexistent and thus generally cannot account for the T 3 -induced modifications in the SNS responsiveness (56) . Usually, modulations of more distal cellular effectors are shown to be responsible for the TH-induced changes in the catecholamine responsiveness (56) . It is possible that these downstream effectors may have been modified by the disruption of ␣ 2 -AR signaling in bone cells, which remains to be investigated. Another point of TH-SNS interaction is the central sympathetic outflow. TH regulates the sympathetic nerve activity, and therefore, it modulates serum and tissue levels of catecholamines (38) . Regardless of a hyperadrenergic state in thyrotoxicosis, there is a reduction of the central sympathetic outflow, which results in reduced serum levels of NE (38, 62) . This paradox is also observed in hypothyroid patients, who clinically manifest signs of decreased adrenergic stimulation but can be expected to have increased serum levels of EP, NE, and its metabolites (35) . Therefore, we evaluated plasma and bone levels of cathecolamines. As predicted, NE and EP were significantly elevated in the plasma of ␣ 2A/2C -AR Ϫ/Ϫ mice, which correlates with the fact that ␣ 2A -and ␣ 2C -AR are the main autoreceptors responsible for limiting NE release from the sympathetic nerves and from chromaffin cells in the adrenal medulla (32), respectively. As expected, T 3 decreased plasma NE in WT mice. In contrast, this effect was not observed in ␣ 2A/2C -AR Ϫ/Ϫ mice, suggesting that ␣ 2 -ARs are important for mediating the TH effects on the sympathetic outflow. Interestingly, bone concentration of NE was significantly elevated in ␣ 2A/2C -AR Ϫ/Ϫ mice and was reduced only by T 3 treatment in ␣ 2A/2C -AR Ϫ/Ϫ mice. The effect of T 3 on NE tissue levels also varies depending on the tissue. For example, thyrotoxicosis was shown to increase or not change NE concentration in the heart and to decrease NE levels in the cerebral cortex (37) . In general, the sympathomimetic features of thyrotoxicosis cannot be explained by increased sympathetic outflow, turnover, or cathecolamine release. On the other hand, TH generally modifies the cellular responsiveness to SNS signals, which overrides the inhibitory or stimulatory effect of thyrotoxicosis or hypothyroidism, respectively, on the central SNS outflow (22, 56) . This may also occur in the bone, since plasma and bone levels of NE could not explain the osteopenic effects of thyrotoxicosis in WT mice.
To get insight on whether ␣ 2A -AR signaling can directly modify bone responsiveness to TH, we evaluated the effect of T 3 on cell growth of calvaria-derived osteoblasts isolated from WT and ␣ 2A/2C -AR Ϫ/Ϫ mice. We first observed a lower cell growth in ␣ 2A/2C -AR Ϫ/Ϫ cells than in WT cells, suggesting that ␣ 2A -AR and/or ␣ 2C -AR signaling in osteoblasts may be important for this process. Accordingly, growth of WT cells was decreased by CLO, an unspecific ␣ 2 -AR agonist, whereas growth of KO cells was increased by this agent. The response of KO cells to CLO may be the result of a CLO-mediated activation of ␣ 2B -AR, which was shown to serve functions in peripheral tissues as well as in the CNS (32) and to be expressed in bone cells, including osteoblasts (19) . As expected, and corroborating previous studies (5, 65, 70) , T 3 decreased the growth of WT cells significantly. However, following the pattern of T 3 effects observed in vivo, this negative effect of T 3 was completely absent or reversed in ␣ 2A/2C -AR Ϫ/Ϫ cells. Additionally, the combination of T 3 with CLO had an additive effect on the inhibition of WT cell growth, whereas T 3 attenuated the positive effect of CLO on KO cell growth. Altogether, these findings suggest that a TH-SNS interaction involving ␣ 2 -AR signaling may occur in osteoblasts to locally regulate bone physiology.
These in vivo results also suggest that nonneuronal ␣ 2 -ARs may be important to directly mediate SNS actions in the bone. As mentioned before, ␣ 2 -AR are classic autoreceptors (presynaptic receptors that inhibit the exocytosis of their own neurotransmitter) that inhibit NE or EP release from adrenergic neurons (of the SNS and CNS) and from chromaffin cells (of the adrenal medulla) to control the sympathetic tonus (58) . However, ␣ 2 -ARs are also expressed as heteroreceptors on nonadrenergic neurons in the peripheral and CNS. Heteroreceptors are presynaptic release-modulating receptors that are activated by neurotransmitters from neighboring neurons (58) . As heteroreceptors, ␣ 2A -ARs can inhibit the release of several neurotransmitters, including serotonin, GABA, and dopamine (23) . In addition to these presynaptic neuronal receptors (auto and heteroreceptors), ␣ 2 -ARs were also identified in many nonneuronal cell types of the body (23), including osteoblasts, osteocytes, osteoclasts, and chondrocytes (19, 61) . Recently, the Dbh promoter was used to drive expression of ␣ 2A -AR exclusively in noradrenergic and adrenergic neurons. Dbh-␣ 2A transgenic mice were crossed with ␣ 2A/2C -AR Ϫ/Ϫ mice to generate animals with selective expression of ␣ 2A -autoreceptors in adrenergic cells (24) . The analysis of these mice confirmed the importance of ␣ 2A -autoreceptors as presynaptic inhibitory feedback receptors to control NE release but, more importantly, showed that the majority of ␣ 2 -AR effects were mediated by ␣ 2 -ARs in nonadrenergic neurons (heteroceptors) or nonneuronal cells. In addition, studies have shown that nonneuronal ␣ 2 -ARs have essential roles in the body (23) . Considering all these features of ␣ 2 -ARs, the TH-SNS interactions to control bone physiology may be extremely complex and may involve ␣ 2 -autoreceptors, ␣ 2 -heteroreceptors, and/or ␣ 2 -ARs present in bone cells. Further studies are required to identify the involvement of these ␣ 2 -ARs subtypes in bone physiology.
It is important to consider that our data are based on a global gene deletion model that has its strengths and limitations (16) . The resistance of ␣ 2A/2C -AR Ϫ/Ϫ mice to the thyrotoxicosisinduced alterations in the bone mass, microstructure, and biomechanical parameters provides strong evidence that TH depends on the integrity of the SNS to control bone physiology, which is an original and important finding. On the other hand, global KO models make it difficult to discriminate direct from indirect effects and the roles of a particular gene (16) . Therefore, our data do not clearly elucidate whether TH interacts with the SNS at the CNS and/or at the local (bone) level. Given the complexity of TH-SNS interaction to control other physiological functions (56) , it is much more likely that the diverse bone responses of WT and KO mice to TH observed in the present study are the result of both central and skeletal SNS-TH interaction. The sites and mechanisms of this interaction are important points for future investigation. In vitro and in vivo studies involving mice with specific deletions of ␣ 2 -AR subtypes in bone cells and also in adrenergic cells (autoreceptors and heteroreceptors) will be valuable tools to elucidate these issues.
Another point to be considered is the life stage of the animals. This study shows that TH depends on the integrity of the SNS to regulate bone mass and structure during the young adulthood of mice, a phase of important bone mass accrual. The TH-SNS interaction during later stages of life may be different and promote different effects on bone mass and structure than those observed in the present study. This matter is supported by evidence that the SNS signaling may vary depending on the life stage. The study by Pierroz et al. (48) , for instance, suggests that ␤ 1 -adrenergic signaling exerts a pre-dominant anabolic stimulus on bone during growth, whereas ␤ 2 -adrenergic signaling predominantly regulates bone turnover during aging.
In summary, the present study provides strong evidence that TH interacts with the SNS to control bone mass and structure in young adult mice. Nevertheless, the mechanisms underlying this interaction and whether it occurs at the central and/or skeletal level or whether the TH-adrenergic interrelationships depend on ␣ 2 -autoreceptors, ␣2-heteroreceptors, and/or nonneuronal ␣ 2 -ARs are important issues raised by this study that need to be clarified in future studies. Finally, the present findings offer new insights into the mechanisms through which TH regulates bone mass, structure, and physiology.
